RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Chapman, MA, Sive, J, Ambrose, J et al. (27 more authors) (2018) RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Blood, 132 (20). pp. 2154-2165. ISSN 0006-4971

Metadata

Item Type: Article
Authors/Creators:
  • Chapman, MA
  • Sive, J
  • Ambrose, J
  • Roddie, C
  • Counsell, N
  • Lach, A
  • Abbasian, M
  • Popat, R
  • Cavenagh, JD
  • Oakervee, H
  • Streetly, MJ
  • Schey, S
  • Koh, M
  • Willis, F
  • Virchis, AE
  • Crowe, J
  • Quinn, MF
  • Cook, G ORCID logo https://orcid.org/0000-0003-0223-3652
  • Crawley, CR
  • Pratt, G
  • Cook, M
  • Braganza, N
  • Adedayo, T
  • Smith, P
  • Clifton-Hadley, L
  • Owen, RG
  • Sonneveld, P
  • Keats, JJ
  • Herrero, J
  • Yong, K
Copyright, Publisher and Additional Information:

© 2018 by The American Society of Hematology. This research was originally published in Blood. Michael A. Chapman, Jonathan Sive, John Ambrose et al, RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature Blood.
Dates:
  • Published: 15 November 2018
  • Accepted: 28 July 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Oncology and Clinical Research (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 07 Aug 2019 09:09
Last Modified: 15 Nov 2019 01:58
Status: Published
Publisher: American Society of Hematology
Identification Number: 10.1182/blood-2018-05-849893
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics


CORE (COnnecting REpositories)